Related Experiment Video

Updated: Aug 24, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Coronary event secondary prevention with statins irrespective of LDL-cholesterol

Leslie L Kerst1, Vincent F Mauro

  • 1The Medical Center of Aurora, 1501 S. Potomac Street, Aurora, CO 80012-5411, USA. leslie.kerst@HealthONEcares.com

The Annals of Pharmacotherapy
|May 4, 2004
PubMed

Insights

Statins show promise for secondary prevention of coronary artery disease in patients with near-optimal or optimal low-density lipoprotein cholesterol (LDL-C). Recent trials challenge earlier findings of attenuated benefit, suggesting potential efficacy.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary artery disease (CAD) remains a leading cause of mortality.
  • Secondary prevention strategies aim to reduce recurrent cardiovascular events.
  • The role of statins in patients with already low cholesterol levels requires clarification.

Purpose of the Study:

  • To review existing evidence on statin use for secondary prevention of CAD.
  • To evaluate the efficacy of statins in patients with near-optimal or optimal baseline low-density lipoprotein cholesterol (LDL-C).

Main Methods:

  • A comprehensive literature search was performed using MEDLINE.
  • Search terms included HMG-CoA reductase inhibitor, statins, coronary disease, post-myocardial infarction, and average cholesterol.
  • Studies focused on patients with baseline LDL-C <130 mg/dL (near-optimal) or <100 mg/dL (optimal) were included.

Main Results:

  • Early secondary prevention trials suggested limited benefit of statins in this patient group.
  • More recent clinical trials have presented findings that contradict earlier observations.
  • Evidence suggests statins may offer benefits even in patients with lower baseline LDL-C.

Conclusions:

  • The use of statins for secondary prevention of CAD in patients near their LDL-C goal is a subject of ongoing debate.
  • Recent trial data indicate that statins may be beneficial in this population.
  • Further research may clarify the optimal role of statins in managing cardiovascular risk.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...